Dr. Reddy's Laboratories has expanded its strategic collaboration with Amgen, one of the world's leading independent biotechnology companies, to market and distribute three of Amgen's medicines in India in the therapy areas of oncology and osteoporosis.
Under this collaboration, according to a press statement from Dr. Reddy's, the company will commercialise Amgen's XGEVA (denosumab), Vectibix (panitumumab) and Prolia (denosumab) in India.
‘Amgen's denosumab, panitumumab and denosumab provide unique treatment options to physicians to address unmet medical needs in the area of oncology and osteoporosis.’
The collaboration leverages the capabilities of both companies, combining Amgen's innovative therapies with Dr. Reddy's deep understanding of patient and physician needs in India, the statement said.
"These medicines provide unique treatment options to physicians to address unmet medical needs in the area of oncology and osteoporosis," said M.V. Ramana, the Executive Vice President & Head of Emerging markets and India Business, Dr Reddy's.
"We are happy to strengthen our relationship with Dr Reddy's. Amgen is committed to addressing unmet medical needs of patients in India, and we are pleased with the commitment Dr Reddy's has demonstrated towards making our medicines available in India as quickly as possible," said Penny Wan, the Amgen Vice President & General Manager, Japan Asia Pacific Region.
Last year, Dr. Reddy's had announced an initial strategic collaboration with Amgen to execute a full range of regulatory and commercial services to seek approval of and launch Amgen's Kyprolis (carfilzomib), BLINCYTO (blinatumomab) and Repatha (evolocumab) in India.